Lesson plan
SRX246
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V 1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders. It is an azetidinone derivative, and was developed from LY-307174 as a lead compound. A Phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder showed a reduction in aggression not any higher than that of the placebo. In another Phase II trial it decreased aggression in patients with Huntington's disease, especially those in the middle and late stages who had a history of violent behavior. It was also being studied for the treatment of post-traumatic stress disorder, but the study was terminated due to lack of funding.
Article summary
SRX246, also known as API-246, is a small-molecule, centrally-active, highly-selective vasopressin V 1A receptor antagonist which is under investigation by Azevan Pharmaceuticals for the treatment of affective and anger disorders. It is an azetidinone derivative, and was developed from LY-307174 as a lead compound. A Phase II activity trial of the drug in the treatment of adults with intermittent explosive disorder showed a reduction in aggression not any higher than that of the placebo. In another Phase II trial it decreased aggression in patients with Huntington's disease, especially those in the middle and late stages who had a history of violent behavior. It was also being studied for the treatment of post-traumatic stress disorder, but the study was terminated due to lack of funding.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.